Disease and Biomarker Profiling of Chinese Lupus Nephritis

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions
Characterize the Molecular Profile of Lupus Nephritis(LN) Patients to Understand Themechanism(s)Contributing to Patient Responsiveness to SocIntegrated Analysis of LN Patient Molecular Profiling and Clinical Annotations to Understand LNdisease Heterogeneity for Disease EndotypeValidate the Association of the Candidate Biomarker Panel Proposed in Table 3-1 With LN Diseasemonitoring
Interventions
OTHER

Trial have no Intervention measures.

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Nan Shen

OTHER

NCT06210464 - Disease and Biomarker Profiling of Chinese Lupus Nephritis | Biotech Hunter | Biotech Hunter